Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
November 08 2023 - 8:00AM
Business Wire
- Accomplished biotechnology and pharmaceutical
executive with over three decades of experience to join Immunome’s
Board of Directors -
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced the appointment of Jean-Jacques “JJ”
Bienaimé to its Board of Directors. Mr. Bienaimé has over three
decades of experience in the biotechnology and pharmaceutical
industries, most recently serving as Chairman and Chief Executive
Officer of BioMarin Pharmaceuticals.
“Immunome is pleased to welcome JJ to the Board of Directors as
we enter our next stage of growth,” stated Clay Siegall, PhD,
President and Chief Executive Officer of Immunome. “JJ has a unique
understanding of how to build a biotechnology company, and he
shares our commitment to improving the lives of cancer patients.
His guidance will be essential as we advance our pipeline of
potential first-in-class and best-in-class targeted cancer
therapies.”
“I am excited to join the Immunome Board of Directors as they
work to bring transformative oncology therapeutics to the patients
most in need,” commented Mr. Bienaimé. “Throughout my career,
pairing a patient-centric approach with operational excellence has
been foundational to success, and I see that same mentality at
Immunome. I look forward to enhancing Immunome’s ability to execute
on Clay’s compelling vision.”
Mr. Bienaimé currently serves as Chairman and Chief Executive
Officer of BioMarin Pharmaceuticals, Inc., a position that he has
held since 2005. Under Mr. Bienaimé’s leadership, BioMarin grew
from a company with a single marketed treatment product to a
multi-billion-dollar commercial organization with numerous approved
products to treat rare diseases, increasing the company’s value
from approximately $400 million to approximately $15 billion. It
has been announced that Mr. Bienaimé will transition to retirement
from his role as Chairman and Chief Executive Officer of BioMarin
effective December 1, 2023. Prior to joining BioMarin, Mr. Bienaimé
served as the Chairman, President and Chief Executive Officer of
Genencor, a targeted oncology biopharmaceutical company that was
ultimately acquired in 2005 by Danisco. Prior to Genencor, Mr.
Bienaimé held the positions of Chairman, President and Chief
Executive Officer of Sangstat Medical. During his time at Sangstat
Medical, Mr. Bienaimé guided the company to profitability, prior to
an eventual acquisition by Genzyme. Prior to joining Sangstat
Medical, Mr. Bienaimé held various senior management positions at
Rhone-Poulenc Rorer Pharmaceuticals and Genentech.
Mr. Bienaimé currently serves on the Board of Directors of
Incyte Corp., a biopharmaceutical company focused on first-in-class
treatments for serious unmet needs, the Pharmaceutical Research and
Manufacturers of America organization (PhMRA) and The Biotech
Industry Organization (BIO). Mr. Bienaimé received his MBA from the
Wharton School at the University of Pennsylvania and his
undergraduate degree from the École Supérieure de Commerce de
Paris.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including immunotherapies, targeted effectors, radioligand
therapies and ADCs. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). These include, but are
not limited to, statements regarding Immunome’s intent to advance
its current pipeline into the clinic, to develop first-in-class and
best-in-class targeted cancer therapies for patients; to bring
transformative oncology therapeutics to the patients most in need;
and other statements regarding management’s intentions, plans,
beliefs, expectations or forecasts for the future. No
forward-looking statement can be guaranteed, and actual results may
differ materially from those projected. Immunome undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise,
except to the extent required by law. We use words such as
“expect,” “look forward to,” “goal,” “will,” and other similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions of the PSLRA.
Such forward-looking statements are based on our expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including, but not limited to, the
ability of Immunome to grow and successfully execute on its
business plan, including advancing its current pipeline into the
clinic and expanding its pipeline through its technology platform,
proprietary toolbox as and when anticipated, and through strategic
transactions, if any; changes in the applicable laws or
regulations; the possibility that Immunome may be adversely
affected by other economic, business, and/or competitive factors;
the risk that regulatory approvals for Immunome’s programs and
product candidates are not obtained, are delayed or are subject to
unanticipated conditions that could adversely affect it; Immunome’s
ability to manage clinical trials or studies; the risk that
pre-clinical data may not be predictive of clinical data; the
complexity of numerous regulatory and legal requirements that
Immunome needs to comply with to operate its business; the reliance
on Immunome’s management and board members and the fact that the
prior experience and successes of the Immunome’s management team
and board members are not indicative of any future success for
Immunome; uncertainties related to Immunome’s capital requirements
and Immunome’s expected cash runway; the failure to obtain,
adequately protect, maintain or enforce Immunome’s intellectual
property rights; and other risks and uncertainties indicated from
time to time described in Immunome’s Annual Report on Form 10-K for
the year ended December 31, 2022, and in Immunome’s other filings
with the SEC. Immunome cautions that the foregoing list of factors
is not exclusive and not to place undue reliance upon any
forward-looking statements which speak only as of the date made.
Moreover, Immunome operates in a very competitive and rapidly
changing environment. New risks emerge from time to time. Except as
required by law, Immunome does not undertake any obligation to
update publicly any forward-looking statements for any reason after
the date of this press release to conform these statements to
actual results or to changes in their expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108166623/en/
Investor Contact Corleen Roche Chief Financial Officer
investors@immunome.com
Media Contact Andrew W. Mielach LifeSci Communications
amielach@lifescicomms.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Apr 2024 to May 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From May 2023 to May 2024